Boenning & Scattergood initiates coverage on Omrix Biopharmaceuticals, Inc. (Nasdaq: OMRI) with a Market Outperform rating and $21 price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE